Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Total Current Liabilities (2019 - 2025)

Historic Total Current Liabilities for Nurix Therapeutics (NRIX) over the last 7 years, with Q4 2025 value amounting to $86.5 million.

  • Nurix Therapeutics' Total Current Liabilities fell 978.88% to $86.5 million in Q4 2025 from the same period last year, while for Nov 2025 it was $86.5 million, marking a year-over-year decrease of 978.88%. This contributed to the annual value of $86.5 million for FY2025, which is 978.88% down from last year.
  • As of Q4 2025, Nurix Therapeutics' Total Current Liabilities stood at $86.5 million, which was down 978.88% from $82.4 million recorded in Q3 2025.
  • In the past 5 years, Nurix Therapeutics' Total Current Liabilities registered a high of $95.9 million during Q4 2024, and its lowest value of $46.8 million during Q2 2021.
  • For the 5-year period, Nurix Therapeutics' Total Current Liabilities averaged around $73.0 million, with its median value being $72.5 million (2022).
  • As far as peak fluctuations go, Nurix Therapeutics' Total Current Liabilities skyrocketed by 5512.13% in 2022, and later tumbled by 978.88% in 2025.
  • Over the past 5 years, Nurix Therapeutics' Total Current Liabilities (Quarter) stood at $66.3 million in 2021, then increased by 6.64% to $70.7 million in 2022, then rose by 23.07% to $87.0 million in 2023, then rose by 10.23% to $95.9 million in 2024, then dropped by 9.79% to $86.5 million in 2025.
  • Its last three reported values are $86.5 million in Q4 2025, $82.4 million for Q3 2025, and $75.6 million during Q2 2025.